

**PART I**
**Statement of Consolidated Audited Results for the Quarter and for the year Ended 31/03/2013**

Sr. No.	Particulars	Rupees in Lacs				
		3 Months ended 31/03/2013	Preceding 3 months ended 31/12/2012	Corresponding 3 months ended 31/03/2012 in the previous year	Year to date figures for the current period ended 31/03/2013	Previous year ended 31/03/2012
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	<b>Income from operations</b>					
i	Gross Sales	159,931	159,420	137,926	628,484	518,067
ii	Less: Excise Duty	3,355	3,318	3,490	12,946	9,070
a	Net Sales	156,576	156,102	134,436	615,538	508,997
b	Other operating income	4,614	4,309	5,364	20,269	17,334
c	Total income from operations (net)	161,190	160,411	139,800	635,807	526,331
2	<b>Expenses</b>					
a	Cost of materials consumed	41,196	39,845	34,235	151,059	118,654
b	Purchases of stock-in-trade	22,282	22,728	13,202	89,926	69,937
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,646)	(5,932)	2,124	(8,950)	(18,571)
d	Employee benefits expense	21,150	23,228	18,942	90,320	75,122
e	Depreciation and amortisation expense	4,656	4,961	3,908	18,283	15,788
f	Other expenses	49,569	55,417	43,016	200,884	172,803
g	Total expenses	137,207	140,247	115,427	541,522	433,733
3	<b>Profit/ (Loss) from Operations before other income, finance costs and exceptional items (1-2)</b>	23,983	20,164	24,373	94,285	92,598
4	Other income	873	1,231	1,538	3,701	5,095
5	<b>Profit/ (Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>	24,856	21,395	25,911	97,986	97,693
6	Finance costs	3,156	3,939	3,534	16,864	18,270
7	<b>Profit/ (Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	21,700	17,456	22,377	81,122	79,423
8	Exceptional items	0	0	0	0	0
9	<b>Profit/ (Loss) from ordinary activities before tax (7+8)</b>	21,700	17,456	22,377	81,122	79,423
10	Tax expense	(5,830)	6,303	4,363	11,949	11,304
11	<b>Net Profit/ (Loss) from ordinary activities after tax (9-10)</b>	27,530	11,153	18,014	69,173	68,119
12	Extraordinary items (net of tax expense)	0	0	0	0	0
13	<b>Net Profit/ (Loss) for the period (11-12)</b>	27,530	11,153	18,014	69,173	68,119
14	Share of profit/ (loss) of associates	0	0	0	0	0
15	Minority interest	(1,284)	(862)	(926)	(3,643)	(2,860)
16	<b>Net Profit/ (Loss) after taxes, minority interest and share of profit/ (loss) of associates (13+14+15)</b>	26,246	10,291	17,088	65,530	65,259
17	Paid-up equity share capital (Face Value Rs. 5/-)	10,237	10,237	10,237	10,237	10,237
18	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year				293,791	248,352
19	<b>Earnings per share (before extraordinary items)</b> <b>(of Rs. 5/- each) (not annualised):</b>					
a	Basic (Rs.)	12.82	5.03	8.35	32.01	31.87
b	Diluted (Rs.)	12.82	5.03	8.35	32.01	31.87
19	<b>Earnings per share (after extraordinary items)</b> <b>(of Rs. 5/- each) (not annualised):</b>					
a	Basic (Rs.)	12.82	5.03	8.35	32.01	31.87
b	Diluted (Rs.)	12.82	5.03	8.35	32.01	31.87

**Notes :**

- The above results for the quarter/ year ended on March 31, 2013 were earlier reviewed by the Audit Committee and then approved by the Board of Directors at their meeting held on May 30, 2013.
- In the consolidated accounts, the accounts of some of the foreign subsidiaries are audited up to December 31, 2012 and subjected to limited review by their auditors for the balance period up to March 31, 2013, wherever applicable.
- The Board of Directors has declared an interim dividend of Rs. 7.50/- [ @ 150% ] per equity share on 204,748,520 equity shares of Rs. 5/- each for the financial year ended on March 31, 2013. The Board of Directors has fixed June 12, 2013 as the Record Date for determining the names of the shareholders entitled to receive the dividend. The dividend will be paid on or after June 17, 2013.
- The changes in Investments during the quarter are as under:  
Zydus BSV Pharma Private Limited [Additional Investment] - Rs. 250 Lacs  
Bayer Zydus Pharma Private Limited [Additional Investment] - Rs. 2,000 Lacs
- The Board of Directors at its meeting held on April 22, 2013 approved the draft Scheme of Amalgamation [Scheme] of its three wholly owned subsidiaries namely - Liva Healthcare Limited [LHL], Zydus Animal Health Limited [Z AHL] and Zydus Pharmaceuticals Limited [ZPL] [collectively referred to as the Transferor Companies] with the Company. The Appointed date of the merger is April 1, 2012. The merger shall be effective, subject to requisite approvals being obtained. Upon the Scheme becoming effective, the investments made in the shares of the Transferor Companies will stand cancelled and in consideration of transfer and vesting of undertakings of the Transferor Companies into the Company, no shares will be issued and allotted by the Company and there will not be any change in the capital structure of the Company.
- Tax expense for the quarter and year ended on March 31, 2013 is net off Alternate Minimum Tax [AMT] Credit amounting to Rs. 9,814 lacs, recognized as an asset in accordance with guidance note issued by the Institute of Chartered Accountants of India.
- Figures of previous reporting periods have been regrouped/ reclassified wherever necessary to correspond with the current reporting period.
- The Company has one segment of activity viz., "Pharmaceuticals".
- The figures of the quarter ended March 31, 2013 are balancing figures between audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the current financial year.
- The detailed standalone results are available on the Company's website: www.zyduscadila.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

The summarised unaudited standalone financial results of the Company are as below:

Particulars	Rupees in Lacs				
	3 Months ended 31/03/2013	Preceding 3 months ended 31/12/2012	Corresponding 3 months ended 31/03/2012 in the previous year	Year to date figures for the current period ended 31/03/2013	Previous year ended 31/03/2012
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
Turnover	72,552	66,191	60,559	265,934	245,650
Profit before Tax	20,232	3,416	14,751	46,853	67,043
Profit after Tax	20,253	3,396	13,940	46,664	65,752

**PART II**

Select information for the Quarter and for the Year Ended 31/03/2013

Particulars	3 Months ended 31/03/2013	Preceding 3 months ended 31/12/2012	Corresponding 3 months ended 31/03/2012 in the previous year	Year to date figures for the current period ended 31/03/2013	Previous year ended 31/03/2012
<b>A PARTICULARS OF SHAREHOLDING</b>					
<b>1 Public shareholding</b>					
- Number of shares	51,610,474	51,610,474	51,610,474	51,610,474	51,610,474
- Percentage of Shareholding	25.21%	25.21%	25.21%	25.21%	25.21%
<b>2 Promoters and Promoter Group Shareholding</b>					
<b>a Pledged / Encumbered</b>					
- Number of shares	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	N.A.	N.A.	N.A.	N.A.	N.A.
- Percentage of shares (as a % of the total share capital of the company)	N.A.	N.A.	N.A.	N.A.	N.A.
<b>b Non - encumbered</b>					
- Number of shares	153,138,046	153,138,046	153,138,046	153,138,046	153,138,046
- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	74.79%	74.79%	74.79%	74.79%	74.79%

Particulars	3 months ended 31/03/2013
<b>B INVESTOR COMPLAINTS [In Numbers]</b>	
Pending at the beginning of the quarter	Nil
Received during the quarter	13
Disposed of during the quarter	13
Remaining unresolved at the end of the quarter	Nil

Audited Consolidated Statement of Assets and Liabilities

Particulars	Rupees in Lacs	
	As at current year end 31/03/2013	As at previous year end 31/03/2012
<b>A EQUITY AND LIABILITIES</b>		
<b>1 Shareholders' funds</b>		
a Share capital	10,237	10,237
b Reserves and surplus	293,791	248,352
<b>Sub-total - Shareholders' funds</b>	304,028	258,589
<b>2 Minority Interest</b>	11,933	9,043
<b>3 Non-current liabilities</b>		
a Long-term borrowings	142,602	132,234
b Deferred tax liabilities (net)	10,046	11,456
c Other long-term liabilities	4,696	4,260
d Long-term provisions	6,448	7,562
<b>Sub-total - Non-current liabilities</b>	163,792	155,512
<b>4 Current liabilities</b>		
a Short-term borrowings	125,538	68,710
b Trade payables	65,576	54,551
c Other current liabilities	51,055	73,092
d Short-term provisions	25,984	22,805
<b>Sub-total - Current liabilities</b>	268,153	219,158
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>747,906</b>	<b>642,302</b>
<b>B ASSETS</b>		
<b>1 Non-current assets</b>		
a Fixed assets	299,520	247,882
b Goodwill on consolidation	86,181	86,221
c Non-current investments	2,115	2,115
d Long-term loans and advances	41,069	24,784
e Other non-current assets	0	0
<b>Sub-total - Non-current assets</b>	428,885	361,002
<b>2 Current assets</b>		
a Current investments	9,332	304
b Inventories	121,357	109,050
c Trade receivables	95,514	92,090
d Cash and cash equivalents	58,208	46,662
e Short-term loans and advances	27,926	27,458
f Other current assets	6,684	5,736
<b>Sub-total - Current assets</b>	319,021	281,300
<b>TOTAL - ASSETS</b>	<b>747,906</b>	<b>642,302</b>

By Order of the Board,  
For Cadila Healthcare Limited,

Pankaj R. Patel  
Chairman & Managing Director

Ahmedabad, May 30, 2013